Lionsgate Studios Corp.
$12.45
▲
1.16%
2026-04-21 07:54:01
NYQ: LION
Explore Lionsgate Studios Corp. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.61 B
Current Price
$12.45
52W High / Low
$12.47 / $5.54
Stock P/E
—
Book Value
$-4.4
Dividend Yield
—
ROCE
11.92%
ROE
11.69%
Face Value
—
EPS
$-0.19
Exp Qtr EPS
—
Sector
—
Industry
—
Employees
—
Beta
—
Debt / Equity
-3.5
Current Ratio
0.42
Quick Ratio
0.42
Forward P/E
52.82
Price / Sales
—
Enterprise Value
—
EV / EBITDA
—
EV / Revenue
—
Rating
Buy
Target Price
$11.28
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
Cons
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Linde plc | $500.31 | 34.25 | $232.11 B | 1.28% | 12.92% | 17.82% | $510.65 / $387.78 | $82.48 |
| 2. | Intuitive Surgical, Inc. | $487.85 | 62.04 | $174.03 B | — | 15.96% | 16.69% | $603.88 / $427.84 | $50.19 |
| 3. | Intel Corporation | $66.34 | — | $332.09 B | 1.14% | -0.01% | 0.02% | $70.33 / $18.25 | $22.88 |
| 4. | Taiwan Semiconductor Manufacturing Company Limited | $374.53 | 31.66 | $1,720.29 B | 1.09% | 29.9% | 35.06% | $2,100 / $816 | $6.54 |
| 5. | Pfizer Inc. | $26.9 | 19.83 | $152.79 B | 6.25% | 10.17% | 8.89% | $28.75 / $21.87 | $15.21 |
| 6. | Thermo Fisher Scientific Inc. | $521.21 | 29.42 | $194.29 B | 0.36% | 8.52% | 13.02% | $643.99 / $385.46 | $141.96 |
| 7. | AbbVie Inc. | NOT FOUND | 86.59 | $360.82 B | 3.4% | 22.16% | 62.25% | $244.81 / $168.54 | $-1.85 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 724.3 M | 475.1 M | 525.9 M | 1.07 B | 628.2 M | — |
| Operating Profit | 45.3 M | -20.3 M | -5.8 M | 120.9 M | 60.2 M | — |
| Net Profit | -46.2 M | -113.5 M | -108.9 M | 21.9 M | -21.9 M | — |
| EPS in Rs | -0.16 | -0.39 | -0.38 | 0.08 | -0.08 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 3.2 B | 2.99 B | 3.08 B | 2.72 B |
| Operating Profit | 227.2 M | 272.6 M | 166.8 M | 118.2 M |
| Net Profit | -128.5 M | -93.5 M | -0.3 M | 11.1 M |
| EPS in Rs | -0.44 | -0.32 | -0 | 0.04 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 5.12 B | 5.1 B | 4.41 B | 4.33 B |
| Total Liabilities | 6.04 B | 6.13 B | 4.85 B | 4.26 B |
| Equity | -1.05 B | -1.15 B | -780.4 M | -261.3 M |
| Current Assets | 1.36 B | 1.37 B | 1.15 B | 1.01 B |
| Current Liabilities | 3.21 B | 3.64 B | 2.11 B | 1.89 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -106.8 M | 488.9 M | 346.1 M | -435 M |
| Investing CF | -35.4 M | -331.8 M | 31.3 M | -180.7 M |
| Financing CF | 84.5 M | -74.9 M | -394.5 M | 525.5 M |
| Free CF | -120.3 M | 479 M | 339.6 M | -441.1 M |
| Capex | -13.5 M | -9.9 M | -6.5 M | -6.1 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 7% | -3.16% | 13.53% | — |
| Earnings Growth % | -37.43% | -31066.67% | -102.7% | — |
| Profit Margin % | -4.02% | -3.13% | -0.01% | 0.41% |
| Operating Margin % | 7.11% | 9.13% | 5.41% | 4.35% |
| Gross Margin % | 30.84% | 36.82% | 28.4% | 29.24% |
| EBITDA Margin % | 55.27% | 49.83% | 59.51% | 61.77% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.